AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03406546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine was used as a sedation agent with less side effect on respiratory system.
Study NCT03406546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Remifentanil was used to prevent cough induced by bronchoscopy.
Study NCT03406546 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngeal mask
Description: Laryngeal mask was used to ensure respiration function during general anesthesia.
Study NCT02856113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin Benzoate
Description: Alogliptin benzoate tablets.
Study NCT02856113 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Alogliptin placebo-matching tablets.
Study NCT03261128 — intervention group
Intervention type: OTHER
Intervention: Self-questionnaire
Description: Filling of a self-questionnaire before each chemotherapy cure
Study NCT03951038 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCIA group
Description: The formula of the PCIA included tramadol 800 mg, flurbiprofen axetil 100mg with saline added up to a volume of 80 ml in total. The PCIA pump was set up with a 5 ml loading dose, a 2 ml bolus dose, a 15 min lockout interval and background infusion at a rate of 1 ml/h.
Study NCT00481156 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation
Study NCT03951038 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lateral TLIPB group
Description: both sides of the spine, a single injection of ropivacaine by nerve stimulating needle under ultrasound-guided between the longissimus and iliocostalis muscles .~The regimen of Lateral TLIPB group is0.2% 20ml ropivacaine and the regimen of PCIA is same with PCIA group.
Study NCT02202746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucitanib
Description: Lucitanib is a potent, orally available selective inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors (FGFR1-3), vascular endothelial growth factor receptors (VEGFR1-3), and platelet-derived growth factor receptors alpha and beta (PDGFR alpha and beta)
Study NCT00481156 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Social Skills Training
Study NCT05751629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab was administered.
Study NCT05751629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib was administered.
Study NCT02533869 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low-dose CT
Description: Low-dose computed tomography for suspected acute uncomplicated appendicitis
Study NCT02533869 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy
Description: All patients diagnosed with an uncomplicated acute appendicitis on low-dose CT-scan will undergo laparoscopic appendectomy to evaluate the sensitivity and specificity of the CT diagnosis
Study NCT02459704 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Semilunar coronally positioned flap
Description: Semilunar coronally positioned flap with enamel matrix derivative (Emdogain) or alone.
Study NCT03205371 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACYW conjugate vaccine
Description: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine; 0.5 milliliter (mL), Intramuscular
Study NCT02459704 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Semilunar coronally positioned flap
Description: Semilunar coronally positioned flap with enamel matrix derivative (Emdogain) or alone.
Study NCT02459704 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enamel matrix derivative (Emdogain)
Description: Enamel matrix derivative associated to semilunar coronally positioned flap (SCPF + EMD - test group)
Study NCT03205371 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MMR
Description: Measles, Mumps, and Rubella Virus Vaccine Live; 0.5 mL, Subcutaneous
Study NCT03205371 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MMR
Description: Measles, Mumps, and Rubella Virus Vaccine Live; 0.5 mL, Subcutaneous
Study NCT03205371 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Varicella
Description: Varicella Virus Vaccine Live; 0.5 mL, Subcutaneous
Study NCT03205371 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varicella
Description: Varicella Virus Vaccine Live; 0.5 mL, Subcutaneous
Study NCT03205371 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-HB-Hib
Description: Diphtheria, Tetanus, Pertussis (acellular component), Hepatitis B, Poliomyelitis (inactivated), and Haemophilus influenzae type-b conjugate vaccine (adsorbed); 0.5 mL, Intramuscular
Study NCT03205371 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTaP-IPV-HB-Hib
Description: Diphtheria, Tetanus, Pertussis (acellular component), Hepatitis B, Poliomyelitis (inactivated), and Haemophilus influenzae type-b conjugate vaccine (adsorbed); 0.5 mL, Intramuscular
Study NCT03205371 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PCV13
Description: Pneumococcal 13-valent Conjugate Vaccine; 0.5 mL, Intramuscular
Study NCT03205371 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV13
Description: Pneumococcal 13-valent Conjugate Vaccine; 0.5 mL, Intramuscular
Study NCT01712100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan
Study NCT01712100 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avapro
Study NCT04426643 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous adipose-derived mesenchymal stem cells
Description: Autologous adipose-derived mesenchymal stem cells mixed with collagen solution injected in submucosal space
Study NCT04426643 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment according to the Clinical protocols
Description: Standard treatment according to the Clinical protocols
Study NCT04426643 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard treatment according to the Clinical protocols
Description: Standard treatment according to the Clinical protocols
Study NCT00959543 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MRI
Description: MRI and clinical investigation
Study NCT02252432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: A bolus of intravenous (IV) ketamine during induction (0.5mg/kg), and an IV infusion of ketamine intraoperatively (5 mcg/kg/min)
Study NCT02252432 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: A bolus of intravenous (IV) ketamine during induction (0.5mg/kg), and an IV infusion of ketamine intraoperatively (5 mcg/kg/min)
Study NCT02252432 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: A single dose of IV methadone (0.2 mg/kg) preinduction.
Study NCT02252432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: A single dose of IV methadone (0.2 mg/kg) preinduction.
Study NCT02252432 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine + methadone
Description: Methadone (0.2 mg/kg) preinduction, a bolus of IV ketamine (0.5 mg/kg) during induction and IV ketamine infusion intraoperatively (5 mcg/kg/min)
Study NCT01468298 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Isostretching
Description: All of patients were accompanied by an individual treatment program composed by 12 sessions of 45 minutes, twice a week. The Isostretching method includes therapeutic different postures, lying, sitting or standing, and the positions were selected according to the postural changes of each patient, identified in the assessment. The Isostretching protocol involves nine positions held for a period of nine breaths, and every three cycles, the patient should rest for a period. The physical therapist used verbal commands to emphasize pursed lip breathing, self growth, curvatures correction and isometric of abdominal, paravertebral, quadriceps and gluteal muscles with the aim of optimizing the stretching and discouraging compensatory movements.
Study NCT01468298 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Global Posture Reeducation
Description: All patients were accompanied by an individual treatment program composed by 12 sessions of 45 minutes, twice a week, involving a series of active gentle movements and postures aimed at realigning joints, stretching shortened muscles and enhancing the contraction of antagonist muscles, thus avoiding postural asymmetry. The positions were selected according to the postural changes of each patient, identified in the assessment and these therapeutic postures imply an active involvement of the patient. The protocol includes three therapeutic postures, lying, sitting or standing, to be held for 15 minutes each. The physical therapist used verbal commands and manual contact to maintain the alignment and make the necessary postural corrections, with the aim of discouraging compensatory movements.
Study NCT02339922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib Citrate
Description: Given PO
Study NCT02339922 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02339922 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT05264480 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone augmentation with minimally invasive corticotomy (piezotomy)
Description: Double layer tunnel flap preparation. Subperiosteally sticky bone containing platelet rich fibrin (PRF) and xenograft is utilized for bone augmentation, while supraperiosteally PRF membranes are used for soft tissue augmentation. Trough the vertical releasing incisions a piezosurgical device is used to perform corticotomy. 1 week after surgery OTM is initiated.
Study NCT05264480 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone augmentation without corticotomy
Description: Double layer tunnel flap preparation. Subperiosteally sticky bone containing platelet rich fibrin (PRF) and xenograft is utilized for bone augmentation, while supraperiosteally PRF membranes are used for soft tissue augmentation. Corticotomy is not performed in this group. 1 week after surgery OTM is initiated.
Study NCT05535049 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical periodontal treatment
Description: Full month non-surgical periodontal treatment procedure was applied to the periodontitis group.
Study NCT01115257 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: vitrectomy
Description: The surgical technique (Group 1) included vitrectomy, with a combination of delamination and segmentation of gliotic tractional membranes using bimanual technique. Silicone oil tamponade was used in eyes with long-standing tractional retinal detachment, as deemed necessary by the surgeon, or in eyes in which a retinal break occurred during the vitrectomy.
Study NCT01115257 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: panretinalphotocoagulation
Description: Panretinal photocoagulation was completed according to guidelines summarized in ETDRS with extensive full subconfluent panretinal photocoagulation.
Study NCT03484598 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPEAC System
Description: A lightweight, non-invasive monitor that is placed on the belly of the biceps muscles to analyze surface electromyography (sEMG) signals that may be associated with generalized tonic-clonic (GTC) seizures. It provides an alarm to alert caregivers of unilateral, appendicular, tonic extension that could be associated with a GTC seizure. The System records and stores sEMG data for subsequent review by a trained healthcare professional.
Study NCT02059967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT02059967 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: image-guided adaptive radiation therapy
Description: Undergo IGART
Study NCT00481156 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Retest in Health Controls
Description: Pre/Post test performance and neuroimaging only
Study NCT01766778 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LAF237 (vildagliptin)
Description: Vildagliptin 50mg capsule
Study NCT01766778 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin maximum tolerance dose
Study NCT02701478 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: N2O exposure
Description: The aim of this study is to evaluate the nociceptive response to a standardized forearm electrical stimulus applied to patients under GA, during surgery, at different End-Tidal concentrations of N2O (ET-N2O: 0%-50%-25%-0%), and to see if ANI and NoL indices show less pain when inhaled N2O is higher.
Study NCT03487796 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MySTYLE
Description: Youth and parents will receive two secure texts or emails to their cell phone or preferred device weekly (for eight weeks). Each text/email will contain a link to new media content designed to (1) improve sexual health knowledge surrounding HIV/AIDs and sexually transmitted infections, (2) increase acceptance of young Black men of all backgrounds (sexual, economic, and family), and (3) improve parent and adolescent relationships and communication.
Study NCT03487796 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Waitlist Control
Description: Youth and parents will not receive intervention materials for the first four months of participation. At the completion of the 4-month follow-up assessment, youth and parents will be eligible to receive two secure texts or emails to their cell phone or preferred device weekly (for eight weeks). Each text/email will contain a link to new media content designed to (1) improve sexual health knowledge surrounding HIV/AIDs and sexually transmitted infections, (2) increase acceptance of young Black men of all backgrounds (sexual, economic, and family), and (3) improve parent and adolescent relationships and communication.
Study NCT02678910 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ovarian Cryopreservation
Description: The ovarian tissue will be removed at a UK Healthcare facility and evaluated for gross disease by a pathologist, embryologist, andrologist or REI physician. The ovarian cortex will be dissected from the medulla and cut into strips in culture/holding media, washed to remove blood cells, and cryopreserved. Cryopreservation will be performed using modifications of the techniques described by Gosden et al. (1994) or will be vitrified using a modification of the techniques of Kuwayama et al., 2007.
Study NCT03522922 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dermaroller
Description: The derma roller used (dermaroller MF8, MT dermaroller Beverly Hills, California USA) is a plastic device with a 12-cm handle that holds a drum-shaped cylinder at the end, similar to a small paint roller, 2 cm in diameter and 2 cm in width. The surface of the cylinder holds 192 titanium needles in eight rows. Each 0.25 mm in diameter and 1.5 mm length sterilized by UV/ Gamma rays.
Study NCT03522922 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Vitamin C
Description: The used vitamin C product was in the form of 17% concentration of L- Ascorbic Acid serum that was encapsulated in gelatinous capsules each contain 1 mg of the serum. The patient instructed to open one capsule and apply its serum content on the treatment area daily at night. This capsule form for topical application help to insure stability of the product and also insure use of equal dose in each application
Study NCT04531033 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus MPH734
Description: After supplementing with oral probiotics, it has been suggested that select probiotics capable of expressing Beta-glucosidase enzyme activity may likewise be effective treatment for lactose intolerance.
Study NCT04531033 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo made to match dietary supplement being tested.
Study NCT04871217 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-NODAGA-RGD PET-imaging
Description: Patients will undergo cardiac 68Ga-NODAGA-RGD PET in order to detect myocardial αVβ3 integrin expression 3-14 days after an acute myocardial infarction or within 4 weeks before and 2 weeks after re-opening of chronic coronary occlusion. Echocardiography of cardiac function will be performed at the time of PET imaging and repeated 6 months later.
Study NCT01995617 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: normal saline, 0.5 mL per dose
Study NCT01995617 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEN-004 Low Dose
Description: The GEN-004 Low Dose contains 10µg of each of the three antigens.
Study NCT01995617 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEN-004 Low Dose + Adjuvant
Description: The GEN-004 Low Dose contains 10µg of each of the three antigens in combination with 350µg of aluminum hydroxide adjuvant.
Study NCT01995617 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEN-004 Mid Dose
Description: The GEN-004 Mid Dose contains 30µg of each of the three antigens.
Study NCT01995617 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEN-004 Mid Dose + Adjuvant
Description: The GEN-004 Mid Dose contains 30µg of each of the three antigens in combination with 350µg of aluminum hydroxide adjuvant.
Study NCT01995617 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEN-004 High Dose
Description: The GEN-004 High Dose contains 100µg of each of the three antigens.
Study NCT01995617 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEN-004 High Dose + Adjuvant
Description: The GEN-004 High Dose contains 100µg of each of the three antigens in combination with 350µg of aluminum hydroxide adjuvant.
Study NCT02776007 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Libre Flash CGMS
Study NCT02776007 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Self-Measurement Blood Glucose
Description: Patients will use their personal glucose meter to perform Self-Measurement Blood Glucose
Study NCT02059967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT02803554 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plasma
Description: Blood plasma from donors aged 25 years or younger
Study NCT00986076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: Enoxaparin 40 mg / 500 ml in Balanced Salt Solution
Study NCT00986076 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Balanced Salt Solution
Description: Intraocular infusion of Balanced Salt solution
Study NCT03612661 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Intervention
Description: Participants in the group intervention will attend eight weekly, 90-minute sessions involving group activities and discussions. They will complete homework between sessions to reinforce learning. The intervention focuses on cultivating attunement to bodily sensations and fostering self-compassion to improve physical and mental health.
Study NCT03970239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography using [11 Carbon]-3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile ([11C]-DASB) and [18 Fluorine]-altanserin ([18F]-altanserin)
Description: Imaging of the serotoninergic system with Positron Emission Tomography using \[11 Carbon\]-3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile (\[11C\]-DASB) and \[18 Fluorine\]-altanserin (\[18F\]-altanserin). During this study, subjects will receive a single intravenous administration of approximately 4 Megabecquerel/kilogram (MBq/kg) of \[11C\]-DASB immediately prior to imaging using Positron Emission Tomography (PET). The effective dose in human body is about 2.1 milliSievert (mSv).~On a separate day, subjects will receive a single intravenous administration of approximately 3.7 MBq/kg of \[18F\]-altanserin for 120 minutes prior to imaging using Positron Emission Tomography (PET). The effective dose in human body is about 8.4 mSv.
Study NCT03970239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography using [18 Fluorine]-altanserin ([18F]-altanserin)
Description: Imaging of the serotoninergic system with Positron Emission Tomography using \[18 Fluorine\]-altanserin (\[18F\]-altanserin). During this study, subjects will receive a single intravenous administration of approximately 3.7 Megabecquerel/kilogram (MBq/kg) of \[18F\]-altanserin 120 minutes prior to imaging using Positron Emission Tomography. The effective dose in human body is about 8.4 mSv.
Study NCT02510144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Skin Prep Chlorhexidine
Description: 3 day preoperative skin prep prior to surgery
Study NCT02510144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Skin Prep Benzoyl Peroxide
Description: 3 day preoperative skin prep prior to surgery